The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man.

The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man.

1. Opioid drugs act on specific receptors which are principally classified into mu, delta and kappa subtypes. Spiradoline (U-62066E) is a kappa-selective agent which has been shown to possess potent anti-nociceptive effects but does not show cross tolerance with morphine. 2. We have assessed the neu...

Descripció completa

Dades bibliogràfiques
Autors principals:	Ur, E, Wright, D, Bouloux, P, Grossman, A
Format:	Journal article
Idioma:	English
Publicat:	1997

Ítems similars

Effect of adrenergic antagonism on the growth hormone, prolactin and cortisol response to a synthetic opioid agonist in man.
per: Bouloux, P, et al.
Publicat: (1986)

Therapeutic Potential of Kappa Opioid Agonists
per: Tyler C. Beck, et al.
Publicat: (2019-06-01)

Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism
per: Madigan L. Bedard, et al.
Publicat: (2024-06-01)

Cardioprotection by kappa-opioid receptor agonist U50488H is mediated by opioidergic regulation but not by calcium current modulation
per: Kook Jin Chun, et al.
Publicat: (2010-02-01)

Novel Kappa-Opioid Receptor Agonist for the Treatment of Cholestatic Pruritus: Systematic Review
per: Adrian Joseph Michel Bailey, et al.
Publicat: (2022-05-01)

Effects of mu- and kappa-2 opioid receptor agonists on pain and rearing behaviors
per: Rossi Heather L, et al.
Publicat: (2007-09-01)

Evidence for the participation of endogenous opioids in the sympathoadrenal response to hypoglycaemia in man.
per: Bouloux, P, et al.
Publicat: (1985)

Fentanyl and Spiradoline Interactions in a Place-Conditioning Black-White Shuttle-Box
per: David J. Mokler, et al.
Publicat: (2010-12-01)

Itching-like behavior: A common effect of the kappa opioid receptor antagonist 5′-guanidinonaltrindole and the biased kappa opioid receptor agonist 6′-guanidinonaltrindole in mice
per: Alan Cowan, et al.
Publicat: (2021-09-01)

Effects of Biased Analogues of the Kappa Opioid Receptor Agonist, U50,488, in Preclinical Models of Pain and Side Effects
per: Ross van de Wetering, et al.
Publicat: (2025-01-01)

Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation
per: Hurramhon Shokirova, et al.
Publicat: (2021-04-01)

Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice
per: Liliana Mititelu Tartau, et al.
Publicat: (2021-02-01)

Diuretic Activity of a Novel Peripherally-Restricted Orally-Active Kappa Opioid Receptor Agonist
per: Tyler C. Beck, et al.
Publicat: (2019-08-01)

Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic
per: Saadet Inan, et al.
Publicat: (2021-09-01)

Sex Differences in Kappa Opioid Receptor Agonist Mediated Attenuation of Chemotherapy-Induced Neuropathic Pain in Mice
per: Kelly F. Paton, et al.
Publicat: (2022-02-01)

The κ-Opioid Receptor Agonist U50488H Ameliorates Neuropathic Pain Through the Ca2+/CaMKII/CREB Pathway in Rats
per: Zhang XM, et al.
Publicat: (2022-05-01)

THE EFFECTS OF OPIOID AGONISTS AND ANTAGONISTS ON ATRIAL-NATRIURETIC-PEPTIDE (ANP) RELEASE IN MAN
per: Borges, F, et al.
Publicat: (1986)

The kappa opioid receptor agonist U50,488H did not affect brain-stimulation reward while it elicited conditioned place aversion in mice
per: Peng Huang, et al.
Publicat: (2020-08-01)

Opioids and stress in man.
per: Grossman, A
Publicat: (1988)

The role of opioid peptides in the hormonal responses to acute exercise in man.
per: Grossman, A, et al.
Publicat: (1984)

Effects of Selective and Mixed-Action Kappa and Delta Opioid Receptor Agonists on Pain-Related Behavioral Depression in Mice
per: S. Stevens Negus, et al.
Publicat: (2024-07-01)

Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus
per: Robert H. Spencer, et al.
Publicat: (2024-10-01)

Distribution, excretion and metabolic pathways of a single parenteral administration of kappa-opioid receptor agonist RU-1205
per: Alexander A. Spasov, et al.
Publicat: (2021-06-01)

Discovery of 7-Azanorbornane-Based Dual Agonists for the Delta and Kappa Opioid Receptors through an In Situ Screening Protocol
per: Fumika Karaki, et al.
Publicat: (2023-10-01)

Agonist-Promoted Phosphorylation and Internalization of the Kappa Opioid Receptor in Mouse Brains: Lack of Connection With Conditioned Place Aversion
per: Chongguang Chen, et al.
Publicat: (2022-05-01)

Sex differences in kappa opioid receptor function and their potential impact on addiction
per: Elena eChartoff, et al.
Publicat: (2015-12-01)

Corrigendum to “Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism” [Addiction Neuroscience, Volume 11, June 2024, 100155]
per: Madigan L. Bedard, et al.
Publicat: (2024-09-01)

Models of neuroinflammation for the assessment of kappa-opioid receptor ligands
per: K. Yu. Kalitin, et al.
Publicat: (2023-05-01)

Molecular mechanism of biased signaling at the kappa opioid receptor
per: Amal El Daibani, et al.
Publicat: (2023-03-01)

Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands
per: Chiara Sturaro, et al.
Publicat: (2022-04-01)

The kappa opioid receptor: from addiction to depression, and back
per: Laurence eLalanne, et al.
Publicat: (2014-12-01)

Nanobody-enabled monitoring of kappa opioid receptor states
per: Tao Che, et al.
Publicat: (2020-03-01)

Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
per: Xin Wang, et al.
Publicat: (2021-11-01)

High-dose naloxone modifies cardiovascular and neuroendocrine function in ambulant subjects.
per: McMurray, R, et al.
Publicat: (1991)

The Kappa Opioid Receptor: Candidate Pharmacotherapeutic Target for Multiple Sclerosis
per: Brian Reed, et al.
Publicat: (2023-11-01)

Signaling underlying kappa opioid receptor-mediated behaviors in rodents
per: Lee-Yuan Liu-Chen, et al.
Publicat: (2022-11-01)

Alcohol-induced plasticity in the dynorphin / kappa-opioid receptor system
per: Sunil eSirohi, et al.
Publicat: (2012-09-01)

Does the kappa opioid receptor system contribute to pain aversion?
per: Catherine M Cahill, et al.
Publicat: (2014-11-01)

Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double‐blind, placebo‐controlled trial
per: Eugene R. Viscusi, et al.
Publicat: (2021-09-01)

Effects of kappa-opioid agonist U-50488 and p38 MAPK inhibitor SB203580 on the spike activity of pyramidal neurons in the basolateral amygdala
per: Konstantin Y. Kalitin, et al.
Publicat: (2024-01-01)